John G Ullman & Associates Inc. Has $1.95 Million Position in Solventum Co. (NYSE:SOLV)

John G Ullman & Associates Inc. cut its position in Solventum Co. (NYSE:SOLV) by 1.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,450 shares of the company’s stock after selling 450 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Solventum were worth $1,945,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC increased its position in Solventum by 22.3% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 47,922 shares of the company’s stock worth $3,341,000 after purchasing an additional 8,730 shares in the last quarter. DekaBank Deutsche Girozentrale increased its position in Solventum by 124.5% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 45,626 shares of the company’s stock worth $3,055,000 after purchasing an additional 25,304 shares in the last quarter. State of Alaska Department of Revenue increased its position in Solventum by 7.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 16,075 shares of the company’s stock worth $1,120,000 after purchasing an additional 1,085 shares in the last quarter. Diversify Wealth Management LLC acquired a new position in Solventum during the 3rd quarter worth approximately $239,000. Finally, Janney Montgomery Scott LLC increased its position in Solventum by 9.8% during the 3rd quarter. Janney Montgomery Scott LLC now owns 42,931 shares of the company’s stock worth $2,993,000 after purchasing an additional 3,848 shares in the last quarter.

Analyst Ratings Changes

SOLV has been the subject of a number of research analyst reports. Piper Sandler upped their price objective on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday. Wells Fargo & Company boosted their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday. Bank of America boosted their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday. Morgan Stanley boosted their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Mizuho started coverage on shares of Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price on the stock. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Solventum has a consensus rating of “Hold” and a consensus price target of $74.71.

Solventum Trading Down 4.7 %

NYSE:SOLV opened at $79.56 on Friday. The firm’s fifty day moving average is $72.51 and its 200-day moving average is $69.96. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05. The firm has a market cap of $13.74 billion and a P/E ratio of 28.93.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.